Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28452921 | 0.95 | GLS (0.90) | GLS | |
| SCHEMBL17654098 | 0.94 | GLS (1.00) | GLS | |
| SCHEMBL17664624 | 0.94 | GLS (1.00) | GLS | |
| SCHEMBL17654174 | 0.94 | GLS (1.00) | GLS | |
| SCHEMBL17654173 | 0.94 | GLS (1.00) | GLS | |
| SCHEMBL26736659 | 0.93 | GLS (0.86) | GLS | |
| SCHEMBL26706154 | 0.93 | GLS (0.89) | GLS | |
| SCHEMBL17654144 | 0.93 | GLS (0.89) | GLS | |
| SCHEMBL17654101 | 0.90 | GLS (0.82) | GLS | |
| SCHEMBL30865653 | 0.89 | GLS (0.80) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| US-20240245680-A1 | Methods of Treating Retinal Vasculopathies | UNITY BIOTECHNOLOGY, INC. | 2024-07-25 | — | — | US | claimed |
| EP-4346813-A1 | METHODS OF TREATING RETINAL VASCULOPATHIES | Unity Biotechnology, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117642163-A | Method for treating retinal vascular disease | 尤尼蒂生物技术公司 | 2024-03-01 | — | — | CN | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2023059212-A1 | COMBINATIONS OF CURCUMIN AND GLUTAMINASE INHIBITORS FOR THE TREATMENT OF CANCER | SIDRA MEDICINE (QA) | 2023-04-13 | — | — | WO | claimed |
| WO-2022251370-A1 | METHODS OF TREATING RETINAL VASCULOPATHIES | UNITY BIOTECHNOLOGY, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| US-20250275964-A1 | METHODS OF INHIBITING LIVER-TYPE GLUTAMINASE, GLS2 | CORNELL UNIVERSITY | 2025-09-04 | — | — | US | disclosed |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | disclosed |
| CN-113302288-B | Methods for controlling cell state transitions in cancer | 新加坡科技研究局 | 2025-03-21 | — | — | CN | disclosed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| CN-106890184-A | Pharmaceutical composition of anti-tumor glutaminase inhibitor and tumor angiogenesis inhibitor and application thereof | 侯以琳 | 2017-06-27 | — | — | CN | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | GLS 3/4885 |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | GLS 98/4885 |
| US-20250275964-A1 | METHODS OF INHIBITING LIVER-TYPE GLUTAMINASE, GLS2 | GLS2, GLS, GLUL | GLS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.